GOV.UK
Document type: drug_safety_update
There are 575 pages with document type ‘drug_safety_update’ in the GOV.UK search index.
Rendering apps
This document type is rendered by:
Supertypes
| Type | Group |
|---|---|
| Navigation document type | other |
| Content purpose | updates-and-alerts |
| User journey | thing |
| Search user need | government |
| Email document type | other |
| Government document type | other |
| Content Purpose Subgroup | updates_and_alerts |
| Content Purpose Supergroup | news_and_communications |
Example pages
- Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements
- Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects
- Quinine: not to be used routinely for nocturnal leg cramps
- Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy
- Paracetamol: updated dosing for children to be introduced
- Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older
- Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
- Domperidone: risks of cardiac side effects
- Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme